BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
Want to see BBOT full AI Analyst Report?
BBOT Stock Chart & Stats
$12.59
--
Market closed
$12.59
--
Day’s Range― - ―
52-Week Range$7.00 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$597.60M
Enterprise Value$668.55M
Total Cash (Recent Filing)$252.28M
Total Debt (Recent Filing)$2.64M
Price to Earnings (P/E)―
Beta0.22
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,107,100
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.59K
Enterprise Value/Ebitda-3.98
Forecast
1Y Price Target
$23.00Price Target Upside82.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and sizable equity provide durable financial flexibility for an R&D-heavy biotech. With debt minimal, BBOT can prioritize clinical development decisions and negotiate partnerships or milestone deals without immediate debt service constraints, lengthening runway versus peers.
Leadership RestructuringA management reset at the CEO/COO/Executive Chair level is a structural governance change aimed at sharpening execution as programs enter Phase 1b. Stronger clinical and operational leadership can materially reduce program delays and improve strategic partner engagement long-term.
Focused Oncology PipelineConcentrated RAS/PI3Kα-focused programs reflect a clear scientific niche and strategic focus. Progressing multiple assets into Phase 1b expands binary de-risking opportunities, increases chances for partnering or licensing, and concentrates resources on indications with defined genomic targets.
Bears Say
Pre-Revenue StatusBeing pre-revenue means the company cannot self-fund commercialization and must rely on external capital for trials and scale-up. This structural funding gap elevates dilution and execution risk, and limits ability to sustain long development timelines without successful milestone events.
High Operating Cash BurnPersistent, large negative operating cash flow is a durable pressure on liquidity; even though cash burn tracks reported losses, the magnitude implies ongoing financing needs. This creates structural runway risk if clinical timelines slip or expected partnerships are delayed.
Negative Returns And Declining EquitySteep negative ROE and falling shareholders' equity signal capital consumption and eroding reserves. Over time this reduces the firm's financial cushion, increases probability of equity raises under dilutive terms, and weakens resilience to trial setbacks or extended development cycles.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $7.00 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $597.60M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
Currently, no data Available
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,107,100 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (82.68% Upside)
$23.00 (82.68% Upside)
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
-61.49%
Trailing 12-Months
Asset Growth
113.44%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
BBOT Stock 12 Month Forecast
Average Price Target
$23.00
▲(82.68% Upside)
Technical Analysis
Ownership Overview
40.79% Insiders
3.19% Mutual Funds
8.39% Other Institutional Investors
46.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---